{"DataElement":{"publicId":"3029363","version":"2","preferredName":"Disease or Disorder Best Outcome of Therapy Chronic Lymphocytic Leukemia Status Type","preferredDefinition":"A description of the best response to therapy for chronic lymphocytic leukemia.","longName":"2946463v1.0:3029355v1.1","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2946463","version":"1","preferredName":"Disease or Disorder Best Outcome of Therapy","preferredDefinition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._Having the most positive qualities._The result of therapy for a given disease or condition in a patient or group of patients.","longName":"2404658v1.0:3194600v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2404658","version":"1","preferredName":"Diseases and Disorders","preferredDefinition":"A definite pathologic process with a characteristic set of signs and symptoms. It may affect the whole body or any of its parts, and its etiology, pathology, and prognosis may be known or unknown.","longName":"C2991","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"005AD6E5-0651-6A35-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-09-09","endDate":null,"createdBy":"PWEST","dateCreated":"2005-09-09","modifiedBy":"ONEDATA","dateModified":"2005-09-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3194600","version":"1","preferredName":"Best Outcome of Therapy","preferredDefinition":"Having the most positive qualities.:The result of therapy for a given disease or condition in a patient or group of patients.","longName":"C25432:C18919","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Best","conceptCode":"C25432","definition":"Having the most positive qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Outcome of Therapy","conceptCode":"C18919","definition":"The result of therapy for a given disease or condition in a patient or group of patients.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D80CD45-BE7A-5B19-E040-BB89AD430E80","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"ZHANGW","dateCreated":"2011-03-02","modifiedBy":"ONEDATA","dateModified":"2011-03-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"747EBAC6-25E8-A734-E040-BB89AD43588E","latestVersionIndicator":"Yes","beginDate":"2009-09-26","endDate":null,"createdBy":"MOROZOFA","dateCreated":"2009-09-26","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3029355","version":"1.1","preferredName":"Chronic Lymphocytic Leukemia Status Type","preferredDefinition":"The most common type of chronic lymphoid leukemia.  It comprises 90% of chronic lymphoid leukemias in the United States.  Morphologically, the neoplastic cells are small, round B-lymphocytes.  This type of leukemia is not considered to be curable with available therapy. (WHO, 2001)_A condition or state at a particular time._Type; a subdivision of a particular kind of thing.","longName":"3029355v1.0","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"60","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Untreated","valueDescription":"Untreated","ValueMeaning":{"publicId":"3029356","version":"1","preferredName":"Untreated","longName":"3029356","preferredDefinition":"No chemotherapy given in the 6 months prior to HCT","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"828EDF08-9C7F-7914-E040-BB89AD4302CA","latestVersionIndicator":"Yes","beginDate":"2010-03-24","endDate":null,"createdBy":"LOHNESC","dateCreated":"2010-03-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","id":"CDEC7B72-EE31-1899-E040-BB89AD430743","beginDate":"2010-03-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2012-11-07","modifiedBy":"ONEDATA","dateModified":"2012-11-07","deletedIndicator":"No"},{"value":"Not assessed","valueDescription":"Not Assessed","ValueMeaning":{"publicId":"2688820","version":"1","preferredName":"Not Assessed","longName":"2688820","preferredDefinition":"An operation in which a term denies or inverts the meaning of another term or construction.: Having determined the value, significance, or extent of.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Negation","conceptCode":"C25594","definition":"An operation in which a term denies or inverts the meaning of another term or construction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Assessment","conceptCode":"C25217","definition":"The final result of a determination of the value, significance, or extent of.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3C3CA061-0C4D-3BF6-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-11","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","id":"CDEC7B72-EE3B-1899-E040-BB89AD430743","beginDate":"2010-03-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2012-11-07","modifiedBy":"ONEDATA","dateModified":"2012-11-07","deletedIndicator":"No"},{"value":"Progressive disease (Prog)","valueDescription":"Progressive disease","ValueMeaning":{"publicId":"3305581","version":"1","preferredName":"Progressive disease","longName":"3305581","preferredDefinition":"One or more of the following: greater than or equal to 50 percent increase in sum of products of 2 or more lymph nodes (1 or more nodes must be greater than or equal to 2 cm) or new nodes; greater than or equal to 50 percent increase in liver or spleen size or new hepatomegaly or splenomegaly; greater than or equal to 50 percent increase in absolute lymphocyte count to greater than or equal to 5 x 10E9/L; transformation to a more aggressive histology","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1F35C76-CCFA-35E8-E040-BB89AD43251D","latestVersionIndicator":"Yes","beginDate":"2011-11-17","endDate":null,"createdBy":"NYCHM","dateCreated":"2011-11-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","id":"CDEC7B72-EE45-1899-E040-BB89AD430743","beginDate":"2010-03-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2012-11-07","modifiedBy":"SBR","dateModified":"2016-07-07","deletedIndicator":"No"},{"value":"Nodular partial remission (NPR)","valueDescription":"Nodular partial response","ValueMeaning":{"publicId":"3131764","version":"1","preferredName":"Nodular partial response","longName":"3131764","preferredDefinition":"Complete response with persistent lymphoid nodules in bone marrow","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E918DAF-15FC-F612-E040-BB89AD433568","latestVersionIndicator":"Yes","beginDate":"2010-08-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2010-08-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","id":"CDEC7B72-EE4F-1899-E040-BB89AD430743","beginDate":"2010-03-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2012-11-07","modifiedBy":"SBR","dateModified":"2016-07-07","deletedIndicator":"No"},{"value":"Stable disease (SD)","valueDescription":"Stable disease","ValueMeaning":{"publicId":"3131766","version":"1","preferredName":"Stable disease","longName":"3131766","preferredDefinition":"No change; not complete remission, partial remission or progressive disease.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E918DAF-1641-F612-E040-BB89AD433568","latestVersionIndicator":"Yes","beginDate":"2010-08-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2010-08-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","id":"CDEC7B72-EE59-1899-E040-BB89AD430743","beginDate":"2010-03-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2012-11-07","modifiedBy":"SBR","dateModified":"2016-07-07","deletedIndicator":"No"},{"value":"Unknown","valueDescription":"Unknown","ValueMeaning":{"publicId":"2572577","version":"1","preferredName":"Unknown","longName":"2572577","preferredDefinition":"Not known, not observed, not recorded, or refused.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E88E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-12-30","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-12-30","modifiedBy":"COLBERTM","dateModified":"2023-09-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CDEC7B72-EE63-1899-E040-BB89AD430743","beginDate":"2012-02-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2012-11-07","modifiedBy":"ONEDATA","dateModified":"2012-11-07","deletedIndicator":"No"},{"value":"Partial remission (PR)","valueDescription":"Partial response","ValueMeaning":{"publicId":"3303186","version":"1","preferredName":"Partial response","longName":"3303186","preferredDefinition":"Greater than or equal to 50 percent decrease in peripheral blood lymphocyte count from pretreatment value; greater than or equal to  50 percent reduction in lymphadenopathy if present pretreatment; greater than or equal to 50 percent reduction in liver and spleen size if enlarged pretreatment; one or more of the following: neutrophils greater than or equal to 1.5 x 10E9/L or 50 percent improvement over baseline, platelets greater than 100 x 10E9/L or 50 percent improvement\r\nover baseline, hemoglobin greater than 11.0 g/dL or 50 percent improvement over baseline","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B17CFD4C-DEE5-EB21-E040-BB89AD437212","latestVersionIndicator":"Yes","beginDate":"2011-11-11","endDate":null,"createdBy":"NYCHM","dateCreated":"2011-11-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","id":"CDEC7B72-EE77-1899-E040-BB89AD430743","beginDate":"2010-03-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2012-11-07","modifiedBy":"SBR","dateModified":"2016-07-07","deletedIndicator":"No"},{"value":"Complete remission (CR)","valueDescription":"Complete response","ValueMeaning":{"publicId":"3625378","version":"1","preferredName":"Complete response","longName":"3625378","preferredDefinition":"No lymphadenopathy; no organomegaly; neutrophils greater than or equal to 1.5 x 10E9/L; platelets greater than 100 x 10E9/L; hemoglobin greater than 11 g/dL; lymphocytes less than 4 x 10E9/L; bone marrow less than 30 percent lymphocytes; absence of constitutional symptoms","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CDEC7B72-EE9D-1899-E040-BB89AD430743","latestVersionIndicator":"Yes","beginDate":"2012-11-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2012-11-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","id":"CDEC7B72-EEB5-1899-E040-BB89AD430743","beginDate":"2012-11-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2012-11-07","modifiedBy":"SBR","dateModified":"2016-06-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3192969","version":"1","preferredName":"CLL Status Type","preferredDefinition":"The most common type of chronic lymphoid leukemia, and comprises 90% of chronic lymphoid leukemias in the United States.  Morphologically, the neoplastic cells are small, round B-lymphocytes.  The clinical course is indolent, but this type of leukemia is not considered to be curable with available therapy. (WHO, 2001) -- 2003:A condition or state at a particular time.:Type; a subdivision of a particular kind of thing.","longName":"C3163:C25688:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Lymphocytic Leukemia","conceptCode":"C3163","definition":"The most common type of chronic lymphoid leukemia.  It comprises 90% of chronic lymphoid leukemias in the United States.  Morphologically, the neoplastic cells are small, round B-lymphocytes.  This type of leukemia is not considered to be curable with available therapy. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9CE62BCE-19DF-3B50-E040-BB89AD4301C2","latestVersionIndicator":"Yes","beginDate":"2011-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-02-22","modifiedBy":"ONEDATA","dateModified":"2011-02-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"CDEC7B72-EE1B-1899-E040-BB89AD430743","latestVersionIndicator":"Yes","beginDate":"2012-11-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2012-11-07","modifiedBy":"NYCHM","dateModified":"2016-11-22","changeDescription":".11/22/16-released.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2695319","version":"1","longName":"NMDP: CDEs to review","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"2964930","version":"1","longName":"2013r1: CLL Pre-HSCT Data","context":"NHLBI"},{"publicId":"3279271","version":"1","longName":"Disease Status","context":"NHLBI"},{"publicId":"2964906","version":"1","longName":"2113r1: CLL Post-HSCT Data","context":"NHLBI"}]},{"publicId":"3553940","version":"1","longName":"BRIDG","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"4133055","version":"1","longName":"Version 3.2","context":"NHLBI"}]},{"publicId":"6685474","version":"1","longName":"Artificial Neural Network Algorithm for BRIDG Mapping","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6685476","version":"1","longName":"Training Set","context":"NCIP"}]}],"AlternateNames":[{"name":"cll_base_tx_best_resp","type":"NMDP_FN","context":"NHLBI"},{"name":"cll_post_bst_resp_hsct","type":"NMDP_FN","context":"NHLBI"},{"name":"PerformedDiagnosis:diseaseStatusCode ","type":"HCT_BRIDG","context":"NHLBI"},{"name":"CLLP_LTHM_cll_bst_resp_inc_unk","type":"NMDP_FN","context":"NHLBI"},{"name":"CLLF_DABH_cll_bst_resp_type","type":"NMDP_FN","context":"NHLBI"}],"ReferenceDocuments":[{"name":"What is the Chronic Lymphocyt","type":"Preferred Question Text","description":"What is the Chronic Lymphocytic Leukemia best response type?","url":null,"context":"NHLBI"},{"name":"What was the best response to HSCT?","type":"Alternate Question Text","description":"What was the best response to HSCT?","url":null,"context":"NHLBI"},{"name":"Best response to line of therapy:","type":"Alternate Question Text","description":"Best response to line of therapy:","url":null,"context":"NHLBI"},{"name":"BRIDG mapping path for CDE:3029363","type":"BRIDG Mapping Path","description":"PerformedDiagnosis.diseaseStatusCode WHERE PerformedDiagnosis > AssessedResultRelationship > PerformedObservation > PerformedClinicalinterpretation.value = \"best result\" AND PerformedDiagnosis.value = \"chronic lymphocytic leukemia(CLL)\"","url":null,"context":"NHLBI"},{"name":"Best response to line of therapy","type":"Application Standard Question Text","description":"Best response to line of therapy","url":null,"context":"NHLBI"},{"name":"Compared to the disease status prior to the preparative regimen, what was the best response to HCT or cellular therapy since the date of the last report?","type":"Alternate Question Text","description":"Compared to the disease status prior to the preparative regimen, what was the best response to HCT or cellular therapy since the date of the last report?","url":null,"context":"NHLBI"},{"name":"Best response to line of therapy","type":"Alternate Question Text","description":"Best response to line of therapy","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"CDECF15F-2147-C777-E040-BB89AD432E1B","latestVersionIndicator":"Yes","beginDate":"2012-11-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2012-11-07","modifiedBy":"KUMMEROA","dateModified":"2021-06-17","changeDescription":".11/22/16-released.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}